Birmingham, West Midlands — (TechSonian) — 21/04/2014 — XOMA Corp (NASDAQ:XOMA) a leader in the discovery and development of therapeutic antibodies, reported 2013 operational highlights and financial results for the 4th quarter and year ended 31st December, 2013.
XOMA Corp (NASDAQ:XOMA) reported the loss of -2.55% and closed at $4.21 with the total traded volume of 1.05 million shares. Its market capitalization is $449.95 million. The stock has a 52-week high price of 9.57 and its 52-week low was recorded at $3.02.
Has XOMA Found The Bottom and Ready To Move Up? Find Out Here
Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) declared that the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE® (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.1
Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -5.62% and ended at $2.52.The total traded volume was 4.98 million shares and market capitalization arrived at $605.17 million. The stock has a 52-week high price of $3.95 and its 52-week low was recorded at $0.55, while during last trade its minimum price was $2.52 and it gained the highest price of $2.72.
Has INO Found The Bottom And Ready To Gain Momentum? Find Out Here
Antares Pharma Inc (NASDAQ:ATRS) recently reported that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis (RA).
Antares Pharma Inc (NASDAQ:ATRS)’s reported the increase of 0.99% to close at $3.07 with the overall traded volume of 1.05 million shares. Its market capitalization on last close reached to $398.91 million. The company has the total of 129.94 million outstanding shares. Its intraday-low price was $3.02 and its hit its day’s highest price at $3.15.
For How Long ATRS Gloss will Attract Investors? Find out via this report
Dynavax Technologies Corporation (NASDAQ:DVAX) released that initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013.
Dynavax Technologies Corporation (NASDAQ:DVAX) the stock remained unchanged and end at $1.50. Its total traded volume during last trading session was 1.12 million shares. The overall market worth of this company is about $394.28 million. The 52 week range of the stock remained $0.98 to $2.68, while its day’s lowest price was $1.46 and its hit its day’s highest price at $1.53.
Should DVAX a Buy or Sell Now? Find Out Here